MBP (85-99) peptide antagonist trifluoroacetate salt manufacturers
|
| | MBP (85-99) peptide antagonist trifluoroacetate salt Basic information |
| Product Name: | MBP (85-99) peptide antagonist trifluoroacetate salt | | Synonyms: | MBP (85-99) peptide antagonist trifluoroacetate salt;H-GLU-LYS-PRO-LYS-VAL-GLU-ALA-TYR-LYS-ALA-ALA-ALA-ALA-PRO-ALA-OH;(4S)-4-amino-5-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid;MBP (85-99) peptide antagonist;Myelin Basic Protein (85-99) Peptide Antagonist;93:PN:US7456252 SEQID:93 claimed sequence;L-Alanine, L-α-glutamyl-L-lysyl-L-prolyl-L-lysyl-L-valyl-L-α-glutamyl-L-alanyl-L-tyrosyl-L-lysyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-prolyl-;MBP 85-99 | | CAS: | 444305-16-2 | | MF: | C70H114N18O21 | | MW: | 1543.78 | | EINECS: | | | Product Categories: | Neurobiology;Neuroscience;Neural Proteins | | Mol File: | 444305-16-2.mol |  |
| | MBP (85-99) peptide antagonist trifluoroacetate salt Chemical Properties |
| Boiling point | 1860.2±65.0 °C(Predicted) | | density | 1.299±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | H2O: >1mg/mL | | form | lyophilized powder | | pka | 3.70±0.10(Predicted) | | Sequence | Glu-Lys-Pro-Lys-Val-Glu-Ala-Tyr-Lys-Ala-Ala-Ala-Ala-Pro-Ala |
| | MBP (85-99) peptide antagonist trifluoroacetate salt Usage And Synthesis |
| Description | MBP (85-99) peptide antagonist, or J5, is a 15 amino acid peptide fragment designed on the binding motif of MBP 85-99 (myelin basic protein 85-99) to HLA-DR2 (human leukocyte antigen-DR2), which competes with and inhibits the binding of MBP (85-99) to HLA-DR2 and IL-2. MBP 85-99 is the the immunodominant epitope of MBP and a major candidate autoantigen in multiple sclerosis (MS), making this peptide a useful tool for MS research. p> | | Biochem/physiol Actions | MBP (85-99) peptide antagonist inhibits binding of MBP 85-99 to HLA-DR2 and IL-2; tool for MS research. MBP (85-99) peptide antagonist inhibits the binding of MBP 85-99 to HLA-DR2 and IL-2 and is a tool for MS research. The peptide antagonist is a 15-mer peptide that competes with Myelin Basic Protein MBP (85-99), the immunodominant epitope of MBP and major candidate autoantigen in multiple sclerosis (MS). | | References | [1] CASSANDRA E SMITH. Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005: 9595-9600. DOI:10.1073/pnas.0504131102.
[2] JOEL N H STERN. Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102 5: 1620-1625. DOI:10.1073/pnas.0409022102.
[3] FRIDKIS-HARELI M. Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.[J]. Clinical & Developmental Immunology, 2013, 2013: 826191. DOI:10.1155/2013/826191. |
| | MBP (85-99) peptide antagonist trifluoroacetate salt Preparation Products And Raw materials |
|